Departamento de Genética, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil.
Int J Neuropsychopharmacol. 2009 Jun;12(5):709-14. doi: 10.1017/S1461145709000212. Epub 2009 Mar 24.
The monoamine oxidase A (MAOA) gene has been extensively related to aggressive, impulsive and violent behaviours. Previous studies have documented the improvement of oppositional symptoms in attention deficit hyperactivity disorder (ADHD) patients with methylphenidate (MPH). However, the effect of the MAOA gene in response to MPH has not been investigated. A sample of 85 boys from an ADHD outpatient service was genotyped for the MAOA-uVNTR polymorphism. The outcome measure was the parent-rated oppositional subscale of the Swanson, Nolan and Pelham Scale - version IV. The scale was applied by child psychiatrists blinded to genotype at baseline and in the first and third months of treatment. A significant interaction between the presence of MAOA high-activity genotype and treatment with MPH over time on oppositional scores was detected during the 3 months' treatment (n=85, F2,136=4.83, p=0.009). These results suggest an effect of the MAOA-uVNTR high-activity genotype on the improvement of oppositional symptoms with MPH treatment.
单胺氧化酶 A（MAOA）基因与攻击性行为、冲动行为和暴力行为密切相关。先前的研究记录了哌醋甲酯（MPH）可改善注意缺陷多动障碍（ADHD）患者的对立症状。然而，MAOA 基因对 MPH 的反应效果尚未得到研究。对来自 ADHD 门诊服务的 85 名男孩进行 MAOA-uVNTR 多态性基因分型。主要观察指标是 Swanson、Nolan 和 Pelham 量表第四版的父母评定对立症状分量表。在基线和治疗第 1 个月和第 3 个月时，由儿童精神科医生对基因型进行盲法评估。在 3 个月的治疗期间（n=85，F2,136=4.83，p=0.009），检测到 MAOA 高活性基因型与 MPH 治疗时间之间的对立评分存在显著的交互作用。这些结果表明，MAOA-uVNTR 高活性基因型对 MPH 治疗改善对立症状有影响。
